Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

Abstract Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving ti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sandeep Bansal, Martin Anderson, Antonio Anzueto, Nicola Brown, Chris Compton, Thomas C. Corbridge, David Erb, Catherine Harvey, Morrys C. Kaisermann, Mitchell Kaye, David A. Lipson, Neil Martin, Chang-Qing Zhu, Alberto Papi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/dac6017c105b4a2b8e947907b8317115
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dac6017c105b4a2b8e947907b8317115
record_format	dspace
spelling	oai:doaj.org-article:dac6017c105b4a2b8e947907b83171152021-12-02T14:49:24ZSingle-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD10.1038/s41533-021-00241-z2055-1010https://doaj.org/article/dac6017c105b4a2b8e947907b83171152021-05-01T00:00:00Zhttps://doi.org/10.1038/s41533-021-00241-zhttps://doaj.org/toc/2055-1010Abstract Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD patients, with a similar safety profile.Sandeep BansalMartin AndersonAntonio AnzuetoNicola BrownChris ComptonThomas C. CorbridgeDavid ErbCatherine HarveyMorrys C. KaisermannMitchell KayeDavid A. LipsonNeil MartinChang-Qing ZhuAlberto PapiNature PortfolioarticleDiseases of the respiratory systemRC705-779ENnpj Primary Care Respiratory Medicine, Vol 31, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the respiratory system RC705-779
spellingShingle	Diseases of the respiratory system RC705-779 Sandeep Bansal Martin Anderson Antonio Anzueto Nicola Brown Chris Compton Thomas C. Corbridge David Erb Catherine Harvey Morrys C. Kaisermann Mitchell Kaye David A. Lipson Neil Martin Chang-Qing Zhu Alberto Papi Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
description	Abstract Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD patients, with a similar safety profile.
format	article
author	Sandeep Bansal Martin Anderson Antonio Anzueto Nicola Brown Chris Compton Thomas C. Corbridge David Erb Catherine Harvey Morrys C. Kaisermann Mitchell Kaye David A. Lipson Neil Martin Chang-Qing Zhu Alberto Papi
author_facet	Sandeep Bansal Martin Anderson Antonio Anzueto Nicola Brown Chris Compton Thomas C. Corbridge David Erb Catherine Harvey Morrys C. Kaisermann Mitchell Kaye David A. Lipson Neil Martin Chang-Qing Zhu Alberto Papi
author_sort	Sandeep Bansal
title	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
title_short	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
title_full	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
title_fullStr	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
title_full_unstemmed	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
title_sort	single-inhaler fluticasone furoate/umeclidinium/vilanterol (ff/umec/vi) triple therapy versus tiotropium monotherapy in patients with copd
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dac6017c105b4a2b8e947907b8317115
work_keys_str_mv	AT sandeepbansal singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT martinanderson singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT antonioanzueto singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT nicolabrown singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT chriscompton singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT thomasccorbridge singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT daviderb singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT catherineharvey singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT morrysckaisermann singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT mitchellkaye singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT davidalipson singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT neilmartin singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT changqingzhu singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd AT albertopapi singleinhalerfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapyversustiotropiummonotherapyinpatientswithcopd
_version_	1718389537329119232

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

Ejemplares similares